OncoMatch/Clinical Trials/NCT05765825

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Is NCT05765825 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including serplulimab and Cisplatin for extensive-stage small-cell lung cancer.

Phase 2RecruitingSichuan UniversityNCT05765825Data as of May 2026

Treatment: serplulimab · Cisplatin · Carboplatin · Etoposide — This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemotherapy-navïe for their extensive-stage disease.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage IV

Measurable disease, as defined by RECIST v1.1

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Adequate hematologic function

Kidney function

Adequate end-organ function

Liver function

Adequate end-organ function

Adequate hematologic and end-organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify